WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) will report its third-quarter 2026 financial results before U.S. markets open Thursday, November 5, as the Wayne-based biotechnology company advances its development and commercialization plans for treatments targeting rare skin diseases and vascular anomalies.
The company has scheduled an investor conference call for 8:30 a.m. Eastern Time that day to discuss its financial performance and provide an update on corporate activities.
Palvella is a clinical-stage biopharmaceutical company developing treatments for serious, rare conditions that currently lack U.S. Food and Drug Administration-approved therapies.
The upcoming results and management update will provide investors with an opportunity to assess the company’s financial position and progress toward its development and commercialization objectives.
Investors can access the live webcast and accompanying presentation slides through the Events & Presentations section of Palvella’s website at www.palvellatx.com.
Telephone participation requires advance registration through the company’s conference call registration link, which provides individual dial-in instructions.
A replay will be available approximately two hours after the call concludes and will remain accessible through the company’s website for 90 days.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.